Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026Business Wire • 10/19/26
5 Attractive Low Price-to-Sales Stocks With Promising Upside PotentialZacks Investment Research • 10/08/26
Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product AwardBusiness Wire • 08/11/26
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company ProgressBusiness Wire • 08/05/26
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International MarketsBusiness Wire • 06/16/26
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company ProgressBusiness Wire • 05/06/26
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark ReportBusiness Wire • 03/10/26
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference TranscriptSeeking Alpha • 02/27/26
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company ProgressBusiness Wire • 02/25/26
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceBusiness Wire • 02/19/26